Elegantly Simple Cancer and Infectious Disease Vaccine Uniquely Addresses Problems Found with Earlier Immunotherapy Approaches

O Cancer elegante simples e a vacina Infectious da doença dirigem-se excepcionalmente aos problemas encontrados com aproximações mais adiantadas do Immunotherapy

Press releases may be edited for formatting or style | November 10, 2010

About TapImmune, Inc.

Taplmmune Inc. (OTCBB:TPIV) is a biotechnology company specializing in the development of innovative cell based immunotherapeutics and vaccines in the areas of oncology and infectious disease. The Company's lead product candidate, the AdhTAP vaccine is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development AdhTAP for the commencement of clinical manufacturing and toxicology studies. The Company is also developing TAP- based prophylactic vaccines. As a vaccine component, the TAP technology has the potential to significantly improve the efficacy of current prophylactic vaccines and enhance the creation of new ones in the fight against pandemic infectious diseases. Learn more online at www.TapImmune.com.

Ensure critical devices are ready to go

Keep biomedical devices ready to go, so care teams can be ready to care for patients. GE HealthCare’s ReadySee™ helps overcome frustrations due to lack of network and device visibility, manual troubleshooting, and downtime.